There would be 100 new research papers, from around the world..... released each month - whereby the PI3K / mTOR pathway, in the human body, is shown to regulate the progression and regression of cancer and other non- cancer disease.
Obviously I do alot of research on the subject. The volume of information that is released is huge. So much so, that in googling research - I nominate the current month, to isolate or reduce the vast quantity of information.
Why not try google for yourself, to best highlight the untold potential of this drug paxalisib. eg Google search: ......"APRIL 2023 PI3K / mTOR"
You will quickly see dozens of high quality research papers, for this April 23 month alone.
------------------------
So how do we know, such information - pretty much ALL, in fact - relates to Paxalisib.
Well here we are from the company in the March 2023 quarterly report - almost begrudgingly acknowledging that paxalisib works outside the brain. (Information that was first suggested on the chatline 4 years ago) -and now we have this declaration..... "In the context of the previously declared strategy..."
Just missing something in promotion I am afraid - rather missing a hell of a lot, may even be an understatement.
Investers have to cop it - means issue of new shares over many years at a discounted share prices, BUT some sort of opportunity for new investors to enter the stock - at a share price that indeed has an explanation, as to why so cheap.
Positive Preclinical Data for Paxalisib in Melanoma In the context of a previously declared strategy to explore the use of paxalisib in cancers outside the central nervous system, Kazia has entered into a number of research collaborations with leading cancer centres.
KZA Price at posting:
20.0¢ Sentiment: Buy Disclosure: Held
